Clinical evidence for cryoablation
We invest in exploring new cryoablation treatment options for our clinicians and patients in the fight against different types of cancer.
With decades of clinical evidence in urological cancers, cryotherapy has emerged as a versatile therapy for the treatment of renal cell carcinoma, pulmonary metastases, bone metastases ad palliation of non-oncologic pain.
EuRECA study
Largest real-world, prospective, multicenter, multidisciplinary study on the use of cryoablation for treatment of RCC in 1700+ patients
MOTION multicentre study
A multicentre study showing that cryoablation offers effective palliation for painful bone metastases with a corresponding increase in quality of life.
ECLIPSE multicentre study
A multicentre study showing that cryoablation offers long-term local disease control and favourable survival rates in patients with metastatic pulmonary tumours..
References:
Guiu et al. Effectiveness and Safety of Selective Internal Radiation Therapy using Yttrium-90 Glass Microspheres for Hepatocellular Carcinoma: Real-world Results from the Multi-center Prospective PROACTIF Cohort of 989 Patients. eClinicalMedicine. Published Online https://doi.org/10.1016/j.eclinm.2026.103884
Garin E, Brenot-Rossi I, Tlili G et al. Abstract 222.4 Treatment of intrahepatic cholangiocarcinoma with Y-90 glass microspheres in the PROACTIF study. ECIO 2024 Book of Abstracts. Cardiovasc Intervent Radiol 47 (Suppl 4); 2024. p.60 https://doi.org/10.1007/s00270-024-03732-x
EPOCH: Mulcahy, M. et al, Radioembolization With Chemotherapy for Colorectal Liver Metastases: A Randomized, Open-Label, International, Multicenter, Phase III Trial (EPOCH). Journal of Clinical Oncology, 20 Sept 2021.
DOSISPHERE: Garin E, Tselikas L, Guiu B et al. Personalized versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. Lancet Gastroenterol Hepatol. 2021, 6: 17-29
LEGACY: Salem R et al. “3020.2: Yttrium-90 Glass Microspheres in the Treatment of Hepatocellular Carcinoma: The LEGACY Study,” CIRSE 2020 Virtual Summit, September 12-15, 2020.
TARGET: Lam, Marnix. A Global Study of Advanced Dosimetry in the Treatment of Hepatocellular Carcinoma with Yttrium-90 Glass Microspheres: Analyses from the TARGET Study. Presented at SIR. March 25, 2021
MOTION: Jack W. Jennings, MD, PhD et al. Cryoablation for Palliation of Painful Bone Metastases: the MOTION Multicenter Study. Radiology: Imaging Cancer 2021; 3(2):e200101,
ECLIPSE: Thierry de Baère, MD et al. The ECLIPSE Study: Efficacy of Cryoablation on Metastatic Lung Tumors with a 5-Year Follow-up. Journal of Thoracic Oncology • August 2021
TheraSphere is a registered trademark of Theragenics Corporation, used under license by Boston Scientific Medical Device Limited, a wholly owned indirect subsidiary of Boston Scientific Corporation.
EuRECA Cryotherapy Registry, https://www.eureca-egistry.com/Public/Home.aspx
Caution:
The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device or at www.IFU-BSCI.com. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France.